Biologic therapies are an efficacious new method of controlling a number of chronic conditions. Data regarding these medications continues to emerge, giving clinicians a greater understanding of their side effects profiles. The biologic agents used in dermatology, particularly the tumor necrosis factor-α inhibitors, have a number of varied dermatologic side effects. In this two-part article, we perform a review of literature regarding cutaneous side effects of infliximab, etanercept, adalimumab, rituximab, efalizumab, and alefacept. In this second part, we discuss injection site reactions, infusion reactions, vasculitis, drug-induced lupus erythematosus, psoriasiform lesions, rebound phenomenon, eczema, atopic dermatitis, and hypersensitivity reactions
CampiP, BenucciM, ManfrediM, DemolyP. Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-[alpha] antagonists. Clin Immunol, 2007; 7:393-403.
3.
MainiRN, BreedveldFC, KaldenJR, et al.Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum, 2004; 50:1051-65.
4.
KapetanovicMC, LarssonL, TruedssonL, et al.Predictors of infusion reactions during infliximab treatment in patients with arthritis. Arthritis Res Ther, 2006; 8:R131.
5.
ColombelJF, LoftusEV, TremaineWJ, et al.The safety profile of infliximab in patients with Crohn's disease: Mayo Clinic experience in 500 patients. Gastroenterology, 2004; 126:19-31.
6.
CohenRD, TsangJF, HanauerSB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol, 2000; 95: 3469-77.
7.
WolbinkGJ, VisM, LemsW, et al.Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum, 2006; 54:711-5.
FarrellRJ, AlsahliM, JeenYT, et al.Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology, 2003; 124:917-24.
10.
KugathasanS, LevyMB, SaeianK, et al.Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol, 2002; 97:1408-14.
11.
SegiuraF, KojimaT, ObaM, et al.Anaphylactic reaction to infliximab in two rheumatoid arthritis patients who had previously received infliximab and resumed. Mod Rheumatol, 2005; 15:201-3.
12.
LequerreT, VittecoqO, KlemmerN, et al.Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol, 2006; 33:1307-14.
13.
MorelandLW, SchiffMH, BaumgartnerSW, et al.Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med, 1999; 130:478-86.
14.
TyringS, GottliebA, PappK, et al.Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet, 2006; 367: 29-35.
15.
PappKA, TyringS, LahfaM, et al.A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol, 2005; 152:1304-12.
16.
GottliebAB, LeonardiCL, GeoffeBS, et al.Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol, 2006; 54(3Suppl 2):S92-100.
17.
ZeltserR, ValleL, TanckC, et al.Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol, 2001; 137:893-9.
18.
EdwardsKR, MowadCM, TylerWB. Worsening injection site reactions with continued use of etanercept. J Drugs Dermatol, 2003; 2:184-7.
19.
LeonardiCL, PappKA, GordonKB, et al.Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol, 2005; 52:425-33.
20.
GordonKB, PappKA, HamiltonTK, et al.Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA, 2003; 290:3073-80.
21.
MenterA, GordonK, CareyW, et al.Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol, 2005; 141:31-8.
22.
GottliebAB, GordonKB, LebwohlMG, et al.Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol, 2004; 3:614-24.
23.
LebwohlM, ChristophersE, LangleyR, et al.An international, randomized, double blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol, 2003; 139:719-27.
Ramos-CasalsM, Brito-ZeronP, MunozS, et al.Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine, 2007; 86:242-51.
26.
MarcouxBS, De BandtM. Vasculitides induced by TNF-α antagonists: a study in 39 patients in France. Joint Bone Spine, 2006; 73:710-3.
27.
TanAL, HoldsworthJ, PeaseC, et al.Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis, 2003; 63:373-4.
28.
ArbachO, GrossWL, GauseA. Treatment of refractory Churg-Strauss-syndrome (CSS) by TNF-alpha blockade. Immunobiology, 2002; 206:496-501.
29.
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
SchneiderSW, StaenderS, SchluterB, et al.Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis. Arch Dermatol, 2006; 142:115-6.
StratigosAJ, AntoniouC, StamathioudakiS, et al.Discoid lupus erythematous eruption induced by infliximab. Clin Exp Dermatol, 2004; 28:150-3.
34.
ShakoorN, MichalskaM, HarrisCA, BlockJA. Drug induced systemic lupus erythematosus associated with etanercept therapy. Lancet, 2002; 359:579-80.
35.
CarlsonE, RothfieldN. Etanercept induced lupus like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum, 2003; 48: 1165-6.
36.
DebandtM, SibiliaJ, Le LoetX, et al.Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French national survey. Arthritis Res Ther, 2005; 7:R545-51.
37.
HighW, MuldrowM, FitzpatrickJ. Cutaneous lupus erythematosus induced by infliximab. J Am Acad Dermatol, 2005; 52:E5.
LouisM, RauchJ, ArmstrongM, FitzcharlesMA. Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol, 2003; 30:2557-62.
42.
VermeireS, NomanM, Van AsscheG, et al.Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology, 2003; 125:32-9.
43.
WollinaU, HanselG, KochA, et al.Tumor necrosis factor alpha inhibitor psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of 6 new patients. Am J Clin Dermatol, 2008; 9:1-14.
44.
FlendrieM, VissersWH, CreemersMC, et al.Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther, 2005; 7:R666-76.
45.
LeeHH, SongIH, FriedrichM. et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumor necrosis factor-α antagonists. Br J Dermatol, 2007; 156: 486-91.
46.
CohenJD, BourneriasI, BuffardV, et al.Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol, 2007; 34:380-5.
47.
RouxCH, BrocqO, LecciaN, et al. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect? J Rheumatol 2007;34:434-7.
48.
PeekR, Scott-JuppR, StrikeH, et al.Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann Rheum Dis, 2006; 65:1259.
49.
DereureO, GuillotB, JorgensenC, et al.Psoriatic lesions induced by antitumor necrosis factor-α treatment: two cases. Br J Dermatol, 2004; 151:506-7.
50.
SfikakisPP, IliopoulosA, ElezoglouA, et al.Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum, 2005; 52:2513-8.
51.
KaryS, WormM, AudringH, et al.New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumor necrosis factor alpha antagonists. Ann Rheum Dis, 2006; 65:405-7.
52.
VereaMM, Del PozoJ, Yebra-PimentelMT, et al.Psoriasiform eruption induced by infliximab. Ann Pharmacother, 2004; 38:54-7.
53.
ManoharanS, WhiteS, GumparthyK. Successful treatment of type I adult-onset pityriasis rubra pilaris with infliximab. Aust J Dermatol, 2006; 47:124-9.
54.
TakahashiH, HashimotoY, Ishida-YamamotoA, et al.Psoriasiform and pustular eruption induced by infliximab. J Dermatol, 2007; 34:468-72.
55.
MossnerR, ThaciD, MohrJ, et al.Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases. Arch Dermatol Res, 2008; 300:101-5.
56.
SladdenSD, ClarkeSD, WettenhallJ. Infliximab-induced palmoplantar pustulosis in a patient with Crohn Disease. Arch Dermatol, 2007; 143:1449.
57.
de GannesGC, GhoreishiM, PopeJ, et al.Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol, 2007; 143:223-31.
58.
SfikakisPP, KolliasG. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol, 2003; 15:380-6.
59.
AeberliD, SeitzM, JuniP, VilligerPM. Increase in peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-α inhibitors. Rheumatology (Oxford), 2005; 44:172-5.
60.
MassaraA, CavazziniPL, TrottaF. In SAPHO syndrome anti-TNF-α therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology (Oxford), 2006; 45:730-3.
61.
MichaëlssonG, KajermoU, MichaëlssonA, HagforsenE. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol 2005;153:1243-4.
PappKA, BressinckR, FretzinS, et al.Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol, 2006; 45: 606-14.
64.
DubertretL, SterryW, BosJD, et al.Clinical experience acquired with the efalizumab (Raptiva) (Clear) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo controlled trial. Br J Dermatol, 2006; 155:170-81.
65.
MenterA, HamiltonTK, TothDP, et al.Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, phase IIIb study. Int J Dermatol, 2007; 46: 637-48.
66.
MaskatiaZK, KooJ. Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine. J Drugs Dermatol, 2007; 6:941-4.
JacobiA, AntoniC, MangerB, et al.Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol, 2005; 52: 522-6.
69.
LowndesS, DarbyA, MeadG, ListerA. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol, 2002; 13:1948-50.
70.
AllenKP, FunkAJ, MandrellTD. Toxic epidermal necrolysis in two rhesus macaques (Macaca mulatta) after administration of rituximab. Comp Med, 2005; 55:377-81.
WitzigTE, VukovAM, HabermannTM, et al.Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol, 2005; 23: 1103-8.
73.
PiroLD, WhiteCA, Grillo-LopezAJ, et al.Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low grade or follicular non-Hodgkin's lymphoma. Ann Oncol, 1999; 10:655-61.
74.
Del PoetaG, Del PrincipeML, BuccisanoF, et al.Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer, 2008; 112:119-28.
75.
ByrdJC, MurphyT, HowardRS, et al.Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol, 2001; 19:2153-64.
76.
EmeryP, FleischmanR, Filipowics-SosnowskaA, et al.The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum, 2006; 54:1390-400.
77.
CohenSB, EmeryP, GreenwaldMW, et al.Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum, 2006; 54:2793-806.
78.
ErranteD, BernardiD, BiancoS, et al.Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma. Ann Oncol, 2006; 17:1720-1.
79.
HeinzerlingLM, UrbanekM, FunkJO, et al.Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous bcell lymphoma. Cancer, 2000; 89:1835-44.
80.
SanyJ, KaiserMJ, JorgensenC, TrapeG. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. Ann Rheum Dis, 2005; 64:1647-9.
81.
WassermanMJ, WeberDA, GuthrieJA, et al.Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol, 2004; 31: 1912-7.
82.
JacobsteinDA, MarkowitzJE, KirschnerBS, et al.Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis, 2005; 11:442-6.
83.
MeasePJ, GladmanDD, RitchlinCT, et al.Adalimumab for the treatment of psoriasis with moderately to severe active psoriatic arthritis. Arthritis Rheum, 2005; 52:3279-89.
84.
MenterA, TyringSK, GordonK, et al.Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol, 2008; 58:106-15.
85.
van de PutteLB, AtkinsC, MalaiseM, et al.Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis, 2004; 63:508-16.
86.
ColombelJF, SandbornWJ, RutgeertsP, et al.Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology, 2007; 132:52-65. [Epub 2006 Nov 29]
87.
WangLC, MedanicaMM, SheaCR, BusbeyS. Infliximab-induced eczematid-like purpura of Doucas and Kapetenakis. J Am Acad Dermatol, 2003; 49:157-8.
88.
ManggeH, GindlS, KenzianH, SchauensteinK. Atopic dermatitis as a side effect of anti-tumor necrosis alpha therapy. J Rheumatol, 2003; 30:2506-7.
89.
WrightRC.Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol, 2003; 49160-1.
90.
ChanJL, Davis-ReedL, KimballAB. Counter regulatory balance: atopic dermatitis in patients under infliximab infusion therapy. J Drugs Dermatol, 2004; 3:315-8.
91.
VergaraG, SilvestreJF, BetllochI, et al.Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol, 2002; 138:1258-9.
92.
BeuthienW, MellinghoffHU, von KempisJ. Skin reaction to adalimumab. Arthritis Rheum, 2004; 50:1690-2.
93.
SoliotisF, GloverM, JawadAS. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis, 2002; 61:850-1.
